Skip to main content

Wegovy Side Effects

Generic name: semaglutide

Medically reviewed by Last updated on Nov 21, 2023.

Note: This document contains side effect information about semaglutide. Some dosage forms listed on this page may not apply to the brand name Wegovy.

Applies to semaglutide: oral tablet. Other dosage forms:


Oral route (Tablet)

Warning: Risk of Thyroid C-Cell TumorsIn rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.Semaglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors

Serious side effects of Wegovy

Along with its needed effects, semaglutide (the active ingredient contained in Wegovy) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking semaglutide:

More common

Other side effects of Wegovy

Some side effects of semaglutide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to semaglutide: oral tablet, subcutaneous solution.


The most commonly reported adverse reactions have included nausea, vomiting, diarrhea, abdominal pain, and constipation.[Ref]


Cases of Medullary thyroid cancer (MTC) have been reported in patients treated with liraglutide in the postmarketing period; the data in these reports is insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans.

GLP- 1 Receptor Agonist:

Postmarketing reports: Medullary thyroid cancer


Very common (10% or more): Nausea (up to 44%), increased amylase (up to 13%), increased lipase (up to 22%), diarrhea (up to 30%), vomiting (up to 24%), constipation (up to 24%), abdominal pain (up to 20%),

Common (1% to 10%): Dyspepsia, eructation, flatulence, gastroesophageal reflux disease, abdominal distention, gastroenteritis, gastroesophageal reflux disease, gastritis, gastroenteritis (viral)

Uncommon (0.1% to 1%): Appendicitis

Frequency not reported: Acute and necrotizing pancreatitis, chronic pancreatitis

In clinical trials for type 2 diabetes, acute pancreatitis was confirmed by adjudication in 7 (0.3 cases per 100 patient years) and 8 patients (0.27 per 100 patient years) in 2 separate trials (compared to 3 and 10 placebo treated patients, respectively). One case of chronic pancreatitis was confirmed. In clinical trials for weight loss, 4 cases of acute pancreatitis were confirmed by adjudication (vs 1 placebo case). In weight loss trials, nausea, diarrhea, vomiting, constipation, and abdominal pain were reported more frequently than in clinical trials for type 2 diabetes.


Rare (less than 0.1%): Anaphylactic reaction

Frequency not reported: Angioedema

Postmarketing reports: Ananaphylaxis, rash, urticaria


In a 2-year trial among patients with type 2 diabetes and high cardiovascular risk, patients treated with this drug experienced a great incidence of diabetic retinopathy complications (3% vs 1.8%). The absolute risk was greater in patients with a history of diabetic retinopathy at baseline (8.2%[drug] vs 5.2%[placebo]) than those without (0.7%[drug] vs 0.4%[placebo]).

Common (1% to 10%): Diabetic retinopathy complications


In the weight loss clinical trials, patients without type 2 diabetes experienced episodes of hypoglycemia.

Very common (10% or more): Hypoglycemia (up to 30% when used in combination with basal insulin)

Common (1% to 10%): Hypoglycemia, decreased appetite, weight loss


Common (1% to 10%): Injection site reactions


Frequency not reported: Development of anti-semaglutide (the active ingredient contained in Wegovy) antibodies

As with other protein and peptide pharmaceuticals, patients receiving this drug have developed anti-semaglutide antibodies. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay, as well as other factor in handling of the sample. For these reasons, the incidence of antibodies cannot be directly compared with other products. Anti-drug antibodies to semaglutide have been reported in up to 1% of patients during clinical trials.


Common (1% to 10%): Cholelithiasis

Uncommon (0.1% to 1%): Cholecystitis

Frequency not reported: Acute gallbladder disease

Cholelithiasis has been reported in 1.5% and 0.4% of patients receiving 0.5 mg and 1 mg weekly, respectively.


Very common (10% or more): Fatigue (up to 11%)

Fatigue was reported in greater than 0.4% of patients.

Nervous system

Very common (10% or more): Headache (up to 14%)

Common (1% to 10%): Dizziness

Uncommon (0.1% to 1%): Dysgeusia


Postmarketing reports: Acute kidney injury, worsening of chronic renal failure


A mean increase in heart rate of 2 to 3 beats per minute (bpm) was reported in clinical trials for type 2 diabetes. In weight loss clinical trials, a mean increase in resting heart rate of 1 to 4 bpm was observed. Maximal changes from baseline at any visit of 10 to 19 bpm (41% vs 34% placebo) and 20 bpm (26% vs 16% placebo) were recorded. In weight loss clinical trials, Hypotension and orthostatic hypotension were more frequently seen in patients on concomitant antihypertensive therapy. Some reactions were related to gastrointestinal reactions and associated volume loss.

Common (1% to 10%): Hypotension, orthostatic hypotension

Uncommon (0.1% to 1%): Syncope

Frequency not reported: Increased heart rate


Common (1% to 10%): Hair loss

Frequently asked questions


1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

2. (2022) "Product Information. Ozempic (1 mg dose) (semaglutide)." Novo Nordisk Pharmaceuticals Inc

3. (2021) "Product Information. Rybelsus (semaglutide)." Novo Nordisk Pharmaceuticals Inc

4. (2021) "Product Information. Wegovy (0.25 mg dose) (semaglutide)." Novo Nordisk Pharmaceuticals Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.